169 related articles for article (PubMed ID: 38741162)
1. Exploring dual diagnosis in opioid agonist treatment patients: a registry-linkage study in Czechia and Norway.
Rolová G; Skurtveit S; Gabrhelík R; Mravčík V; Odsbu I
Addict Sci Clin Pract; 2024 May; 19(1):37. PubMed ID: 38741162
[TBL] [Abstract][Full Text] [Related]
2. Gender differences in physical morbidity in opioid agonist treatment patients: population-based cohort studies from the Czech Republic and Norway.
Rolová G; Eide D; Gabrhelík R; Odsbu I; Clausen T; Skurtveit S
Subst Abuse Treat Prev Policy; 2023 Jul; 18(1):47. PubMed ID: 37507709
[TBL] [Abstract][Full Text] [Related]
3. Exploring mental health comorbidities and opioid agonist treatment coverage among people in prison: A national cohort study 2010-2019.
Bukten A; Skjærvø I; Stavseth MR
Drug Alcohol Depend; 2023 Sep; 250():110896. PubMed ID: 37515826
[TBL] [Abstract][Full Text] [Related]
4. Cause-Specific Mortality among Patients in Treatment for Opioid Use Disorder in Multiple Settings: A Prospective Comparative Cohort Study.
Eide D; Skurtveit S; Clausen T; Hesse M; Mravčík V; Nechanská B; Rolova G; Thylstrup B; Tjagvad C; Seid AK; Odsbu I; Gabrhelík R
Eur Addict Res; 2023; 29(4):272-284. PubMed ID: 37385232
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway.
Aas CF; Vold JH; Skurtveit S; Lim AG; Ruths S; Islam K; Askildsen JE; Løberg EM; Fadnes LT; Johansson KA;
Subst Abuse Treat Prev Policy; 2020 Sep; 15(1):68. PubMed ID: 32883319
[TBL] [Abstract][Full Text] [Related]
6. A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data.
Morin KA; Eibl JK; Gauthier G; Rush B; Mushquash C; Lightfoot NE; Marsh DC
Harm Reduct J; 2020 Jul; 17(1):51. PubMed ID: 32703310
[TBL] [Abstract][Full Text] [Related]
7. Psychiatric comorbidities in opioid-dependent patients undergoing a replacement therapy programme in Spain: The PROTEUS study.
Roncero C; Barral C; Rodríguez-Cintas L; Pérez-Pazos J; Martinez-Luna N; Casas M; Torrens M; Grau-López L
Psychiatry Res; 2016 Sep; 243():174-81. PubMed ID: 27416536
[TBL] [Abstract][Full Text] [Related]
8. Opioid maintenance treatment in the Czech Republic, Norway and Denmark: a study protocol of a comparative registry linkage study.
Gabrhelík R; Handal M; Mravčík V; Nechanská B; Tjagvad C; Thylstrup B; Hesse M; Minařík J; Jarkovský J; Bukten A; Clausen T; Skurtveit S
BMJ Open; 2021 May; 11(5):e047028. PubMed ID: 33972343
[TBL] [Abstract][Full Text] [Related]
9. Neonatal outcomes after fetal exposure to methadone and buprenorphine: national registry studies from the Czech Republic and Norway.
Nechanská B; Mravčík V; Skurtveit S; Lund IO; Gabrhelík R; Engeland A; Handal M
Addiction; 2018 Jul; 113(7):1286-1294. PubMed ID: 29443414
[TBL] [Abstract][Full Text] [Related]
10. Opioid agonist therapy and mortality among First Nations and other residents with concurrent alcohol use disorder in British Columbia, Canada: A population-based cohort study.
Barker B; Min JE; Homayra F; Piske M; Sabeti S; Meilleur L; Nosyk B; Wieman N
Drug Alcohol Depend; 2023 Sep; 250():110908. PubMed ID: 37544037
[TBL] [Abstract][Full Text] [Related]
11. The complex relation between access to opioid agonist therapy and diversion of opioid medications: a case example of large-scale misuse of buprenorphine in the Czech Republic.
Mravčík V; Janíková B; Drbohlavová B; Popov P; Pirona A
Harm Reduct J; 2018 Dec; 15(1):60. PubMed ID: 30514306
[TBL] [Abstract][Full Text] [Related]
12. Hospitalization of children after prenatal exposure to opioid maintenance therapy during pregnancy: a national registry study from the Czech Republic.
Skurtveit S; Nechanská B; Handal M; Mahic M; Mravčík V; Gabrhelík R
Addiction; 2019 Jul; 114(7):1225-1235. PubMed ID: 30725515
[TBL] [Abstract][Full Text] [Related]
13. Dispensation of attention deficit hyperactivity disorder (ADHD) medications in patients receiving opioid agonist therapy; a national prospective cohort study in Norway from 2015 to 2017.
Vold JH; Aas C; Skurtveit S; Odsbu I; Chalabianloo F; Halmøy A; Johansson KA; Fadnes LT
BMC Psychiatry; 2020 Mar; 20(1):119. PubMed ID: 32164615
[TBL] [Abstract][Full Text] [Related]
14. Mental disorder prevalence in chronic pain patients using opioid versus non-opioid analgesics: A registry-linkage study.
Gjerde LC; Skurtveit S; Handal M; Nesvåg R; Clausen T; Lid TG; Hamina A; Borchgrevink PC; Odsbu I
Eur J Pain; 2023 Aug; 27(7):884-895. PubMed ID: 37133299
[TBL] [Abstract][Full Text] [Related]
15. The impact of the 2014 military conflict in the east of Ukraine and the Autonomous Republic of the Crimea among patients receiving opioid agonist therapies.
Meteliuk A; Sazonova Y; Goldmann E; Xu S; Liutyi V; Liakh T; Spirina T; Lekholetova M; Islam Z; Ompad DC
J Subst Use Addict Treat; 2024 May; 160():209312. PubMed ID: 38336264
[TBL] [Abstract][Full Text] [Related]
16. Psychiatric and Substance Use Comorbidity in Treatment-Seeking Injection Opioid Users Referred From Syringe Exchange.
Kidorf M; Solazzo S; Yan H; Brooner RK
J Dual Diagn; 2018; 14(4):193-200. PubMed ID: 30332349
[TBL] [Abstract][Full Text] [Related]
17. Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs.
Scott TM; Arnsten J; Olsen JP; Arias F; Cunningham CO; Rivera Mindt M
Addict Sci Clin Pract; 2021 Oct; 16(1):64. PubMed ID: 34689841
[TBL] [Abstract][Full Text] [Related]
18. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017.
Aas CF; Vold JH; Skurtveit S; Odsbu I; Chalabianloo F; Lim AG; Johansson KA; Fadnes LT
Subst Abuse Treat Prev Policy; 2020 Jun; 15(1):44. PubMed ID: 32605625
[TBL] [Abstract][Full Text] [Related]
19. Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study.
Bech AB; Clausen T; Waal H; Šaltytė Benth J; Skeie I
BMC Health Serv Res; 2019 Jul; 19(1):440. PubMed ID: 31266495
[TBL] [Abstract][Full Text] [Related]
20. High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis.
Socías ME; Wood E; Lake S; Nolan S; Fairbairn N; Hayashi K; Shulha HP; Liu S; Kerr T; Milloy MJ
Addiction; 2018 Dec; 113(12):2250-2258. PubMed ID: 30238568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
